公开(公告)号：US11162944B2

公开(公告)日：2021-11-02

申请号：US15752037

申请日：2016-08-12

Applicant: Diagnostig LTD.

Inventor： Mark Stephen Baird ,  Christopher David Gwenin ,  Juma'a Raheem Najeem Al-Dulayymi ,  Mohsin Omar Mohammed

IPC: A61K39/00 ,  A61K39/02 ,  A61K39/04 ,  G01N33/569 ,  C07H15/04 ,  C07H15/18 ,  G01N33/543

Abstract: A method of determining whether an individual is infected with a mycobacterial disease, the method comprising: (a) providing a system which comprises an antigen; (b) contacting the system with a sample obtained from the individual; and (c) detecting the presence or absence of binding of a biomarker in the sample with the antigen; wherein the antigen is an arabinose ester of a mycolic acid or an analogue thereof.

公开(公告)号：US11090364B2

公开(公告)日：2021-08-17

申请号：US16306243

申请日：2017-06-02

Applicant: SANOFI

Inventor： Stefan Petry ,  Oliver Plettenburg ,  Norbert Tennagels ,  Ulrich Werner

IPC: A61K38/28 ,  A61K47/54 ,  A61P3/08 ,  C07H13/10 ,  C07K14/62 ,  C07H19/04 ,  C07H19/056 ,  C07H15/12 ,  C07H15/04 ,  C07H13/08 ,  C07H15/26

Abstract: The invention describes novel conjugates of formula (I) of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein allowing a reversible release of the pharmaceutical agent depending on the glucose concentration.

公开(公告)号：US20210206794A1

公开(公告)日：2021-07-08

申请号：US17208831

申请日：2021-03-22

Applicant: MGI Tech Co., Ltd. ,  BGI Shenzhen

Inventor： Handong Li ,  Snezana Drmanac ,  Radoje Drmanac ,  Xun Xu ,  Lingling Peng ,  Scott Gablenz

IPC: C07H15/04 ,  C07H19/10 ,  C07H19/20 ,  C12Q1/6869 ,  C07H21/04

Abstract: Reversibly blocked nucleoside analogues and methods of using such nucleoside analogues for sequencing of nucleic acids are provided.

公开(公告)号：US20210145974A1

公开(公告)日：2021-05-20

申请号：US17046221

申请日：2019-04-08

Applicant: YALE UNIVERSITY

Inventor： David Spiegel ,  David Caianiello ,  Mengwen Zhang

IPC: A61K47/64 ,  A61K45/06 ,  C07H15/04 ,  C07D419/02 ,  C07D413/02 ,  C07D309/04 ,  C07D261/20

Abstract: The present invention is directed to bifunctional small molecules which contain a circulating protein binding moiety (CPBM) linked through a linker group to a cellular receptor binding moiety (CRBM) which is a membrane receptor of degrading cell such as a hepatocyte or other degrading cell. In embodiments, the (CRBM) is a moiety which binds to asialoglycoprotein receptor (an asialoglycoprotein receptor binding moiety, or ASGPRBM) of a hepatocyte. In additional embodiments, the (CRBM) is a moiety which binds to a receptor of other cells which can degrade proteins, such as a LRP1, LDLR, FcγRI, FcRN, Transferrin or Macrophage Scavenger receptor. Pharmaceutical compositions based upon these bifunctional small molecules represent an additional aspect of the present invention. These compounds and/or compositions may be used to treat disease states and conditions by removing circulating proteins through degradation in the hepatocytes or macrophages of a patient or subject in need of therapy. Methods of treating disease states and/or conditions in which circulating proteins are associated with the disease state and/or condition are also described herein.

公开(公告)号：US10988508B2

公开(公告)日：2021-04-27

申请号：US15568559

申请日：2016-04-22

Applicant: Catherine Leimkuhler Grimes ,  James E. Melnyk ,  Kristen E. Demeester ,  Hai Liang

Inventor： Catherine Leimkuhler Grimes ,  James E. Melnyk ,  Kristen E. Demeester ,  Hai Liang

IPC: C07K9/00 ,  C07H15/04 ,  C07H15/12 ,  C12N1/20 ,  A61K38/00 ,  A61K39/02 ,  A61K39/00 ,  C07H11/04 ,  C07H5/06

Abstract: The present invention provides N-acetyl-muramic acid (NAM) derivatives having Formula I, wherein Xa is selected from the group consisting of X1-X59, Ya is selected from the group consisting of H, monophosphate, uridine diphosphate and ethyl azide linker prepared from 2-azido-ethanol, and Za is selected from the group consisting of OH, an ethylene diamine coupled fluorophore, a peptide and a peptide with an ethylene diamine coupled fluorophore, wherein the peptide is selected from the group consisting of a monopeptide, a dipeptide, a tripeptide and a pentapeptide. Also provided are methods for synthesizing NAM derivatives and methods for modulating Nod2 in cells, modifying bacterial cell wall or modulating innate immune response by a subject to bacterial cells upon exposure to NAM derivatives.

公开(公告)号：US10988501B2

公开(公告)日：2021-04-27

申请号：US16094845

申请日：2017-04-21

Applicant: Complete Genomics, Inc. ,  BGI Shenzhen

Inventor： Handong Li ,  Snezana Drmanac ,  Radoje Drmanac ,  Xun Xu ,  Lingling Peng ,  Scott Gablenz

IPC: C07H19/10 ,  C07H19/20 ,  C07H15/04 ,  C12Q1/6869 ,  C07H21/04

Abstract: Reversibly blocked nucleoside analogues and methods of using such nucleoside analogues for sequencing of nucleic acids are provided.

公开(公告)号：US20210102949A1

公开(公告)日：2021-04-08

申请号：US17024913

申请日：2020-09-18

Applicant: The Governing Council of the University of Toronto ,  University Health Network

Inventor： Mark Nitz ,  Landon J. Edgar ,  Bradly G. Wouters ,  David Hedley ,  Lisa M. Willis ,  Matthew A. Lumba ,  Hanuel Park ,  Ravi N. Vellanki

IPC: G01N33/58 ,  C07D421/06 ,  C07D345/00 ,  C07H15/04 ,  G01N33/569

Abstract: A compound of formula (I): as described herein and methods and uses thereof as for mass tagging a biosensor or biologically active material.

公开(公告)号：US20210054017A1

公开(公告)日：2021-02-25

申请号：US16799669

申请日：2020-02-24

Applicant: Ionis Pharmaceuticals, Inc.

Inventor： Punit P. Seth ,  Thazha P. Prakash ,  Michael T. Migawa ,  Eric E. Swayze

IPC: C07H21/00 ,  C12N15/113 ,  C07H13/08 ,  C07H15/04 ,  C07H15/14 ,  C07H19/056 ,  C07H19/06 ,  C07H19/16 ,  C07H13/04 ,  C07H13/10 ,  C12P19/34

Abstract: Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the gomeric compounds are conjugated to N-Acetylgalactosamine or to N-Acetylgalactosamine anaologues.

公开(公告)号：US10907142B2

公开(公告)日：2021-02-02

申请号：US16268989

申请日：2019-02-06

Applicant: Genzyme Corporation

Inventor： Yunxiang Zhu ,  Seng H. Cheng ,  Canwen Jiang ,  Luis Z. Avila

IPC: C07H15/04 ,  C12N9/96 ,  C12N9/16 ,  C12N9/26 ,  A61K47/54 ,  A61K38/47

Abstract: The invention provides methods for the synthesis of oligosaccharides comprising an aminooxy group. The invention further provides oligosaccharides comprising an aminooxy group, methods for coupling oligosaccharides comprising an aminooxy group to glycoproteins, and oligosaccharide-protein conjugates. Also provided are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-protein conjugate.

公开(公告)号：US10894803B2

公开(公告)日：2021-01-19

申请号：US15759879

申请日：2016-09-15

Applicant: NANOMEDSYN ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS ,  UNIVERSITE DE MONTPELLIER

Inventor： Alain Morere ,  Afitz Da Silva ,  Elise Bouffard ,  Khaled El Cheikh ,  Jean-Olivier Durand ,  Marie Maynadier ,  Ilaria Basile

IPC: C07H15/04 ,  C07H15/18 ,  C07H15/26 ,  A61K47/69 ,  A61K38/47 ,  A61K41/00 ,  A61K47/26 ,  A61K49/00 ,  C12N9/24 ,  C12N9/96

Abstract: The subject matter of the present invention is a compound characterized in that it has the general formula (I): in which P1, X, n, A, L and L1 are as defined in Claim 1. The present invention also relates to a process for preparing said compounds (I) and to the use thereof for targeting the cation-independent mannose 6-phosphate receptor (CI-M6PR). The subject matter of the invention is also a conjugate of formula (III): in which P1, X, n, A, L and L′1 are as defined in Claim 6, and the use thereof: —in a method for therapeutic treatment of the human or animal body, in particular chosen from enzyme replacement therapy, photodynamic therapy or cancer treatment, and/or—in a method of diagnosis, in particular of diseases or of ailments associated with an increase or with a decrease in CI-M6PR expression.